Sleep and Cognition After Atripla to Stribild Switch
Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Atripla and Stribild are two FDA-Approved one pill a day combination antiretroviral
medications given for the treatment of HIV. Both drugs are reasonably well tolerated.
However, efavirenz, a component of Atripla, is known to cause "mental" side effects.
This proposal aims to assess whether a switch from Atripla to Stribild for 12 weeks will be
associated with reversal of sleep and cognitive disturbances. Demonstrating changes upon
withdrawal of drug and substitution of a drug regimen not known to have an impact on sleep
and cognition may represent the best option to determine whether use of efavirenz is
associated with effects on sleep and cognition beyond the immediate period following
initiation of drug.
Phase:
Phase 4
Details
Lead Sponsor:
University of Hawaii
Collaborator:
Gilead Sciences
Treatments:
Cobicistat Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Elvitegravir Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir